Point-Of-Care Ultra-Portable Single-Molecule Bioassays for One-Health

Screening asymptomatic organisms (humans, animals, plants) with ahigh-diagnostic accuracy using point-of-care-testing (POCT) technologies,though still visionary holds great potential. Convenient surveillance requireseasy-to-use, cost-effective, ultra-portable but highly reliable,in-vitro-diagnostic devices that are ready for use wherever they are needed.Currently, there are not yet such devices available on the market, but there area couple more promising technologies developed at readiness-level 5: theClustered-Regularly-Interspaced-Short-Palindromic-Repeats (CRISPR)lateral-flow-strip tests and the Single-Molecule-with-a-large-Transistor (SiMoT)bioelectronic palmar devices. They both hold key features delineated by theWorld-Health-Organization for POCT systems and an occurrence offalse-positive and false-negative errors<1–5% resulting indiagnostic-selectivity and sensitivity>95–99%, while limit-of-detections are offew markers. CRISPR-strip is a molecular assay that, can detect down to fewcopies of DNA/RNA markers in blood while SiMoT immunometric andmolecular test can detect down to a single oligonucleotide, protein marker, orpathogens in 0.1mL of blood, saliva, and olive-sap. These technologies canprospectively enable the systematic and reliable surveillance of asymptomaticones prior to worsening/proliferation of illnesses allowing for timely diagnosisand swift prognosis. This could establish a proactive healthcare ecosystemthat results in effective treatments for all living organisms generating diffuseand well-being at efficient costs